Vireo Growth (VREOF) Non Operating Interest Expenses (2024 - 2025)
Vireo Growth (VREOF) reported Non Operating Interest Expenses of $607085.0 for Q3 2025, up 153.02% on a YoY basis from $239932.0 in Q3 2024, and up 37.03% sequentially from $443031.0 in Q2 2025.
Vireo Growth (VREOF) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
Vireo Growth (VREOF) has 2 years of Non Operating Interest Expenses data on file, last reported at $607085.0 in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Interest Expenses rose 153.02% year-over-year to $607085.0; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (changed N/A YoY), and the FY2024 full-year result was $859535.0, up 8.53% from the prior year.
- Non Operating Interest Expenses improved to $607085.0 in Q3 2025, from $443031.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $607085.0 in Q3 2025 to a low of $166542.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 607,085.00 |
| Jun 30, 2025 | 443,031.00 |
| Mar 31, 2025 | 166,542.00 |
| Dec 31, 2024 | 207,643.00 |
| Sep 30, 2024 | 239,932.00 |
| Jun 30, 2024 | 189,946.00 |
| Mar 31, 2024 | 222,014.00 |